2 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy SM101, Placebo - Immunoglobulin A Nephropathy | Phase 2 | Withdrawn | Baxalta now part of Shire | 2015-12-31 | 2022-02-07 | |
| Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy Fostamatinib Disodium tablet 100 mg, Fostamatinib Disodium tablet 150 mg - IGA Nephropathy | Phase 2 | Withdrawn | Rigel Pharmaceuticals | 2015-09-01 | 2015-10-23 |
Autoimmune Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Glomerulonephritis (2) · Immune System Diseases (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Nephritis (2) · Urogenital Diseases (2) · Urologic Diseases (2)
fostamatinib (1)
Baxalta now part of Shire (1) · Rigel Pharmaceuticals (1)
2015 (1)